Is Axcella Health Inc. (AXLA) a Buy, Sell, or Hold?
NASDAQ : AXLA
Axcella Health Inc.
$4.58 USD
$0 (0.0%)
- Volume
- 6.78K
- Average Volume
- 37.08K
- Market Capitalization
- $12.5M
- P/E Ratio
- -3.61
- Dividend Yield
- 0.00%
- Price Target
- $60.00
- Year High
- $4.58
- Year Low
- $0.36
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.21
Company Overview
NASDAQ
Craig R. Jalbert CIRA
Biotechnology
Healthcare
AXLA
11
US
USD
Liquidity Metrics
0.52
1.21
1.21
1.21
0.00
Sales & Valuation
-$
0.00
70.41
-0.18
-1.09
Profitability
-$1.27
-$81.19M
0.00%
0.00%
-620.40%
-428.94%
P/E Metrics
-3.61
0.07
0.07
Analyst Price Target & Rating
$60.00
$60.00
$60.00
0/5
10 Analysts
-92.37%
Financial Health Scores
-80.09
3/9
-$2.27M
$9.28M
$11.54M
-$45.64M
Key Metrics (TTM)
-$2.48M
0.00
0.03
1.21
-620.40%
-1142.66%
-27.69%
-559.96%
0 days
Company Executives
| Name | Title |
|---|---|
| William R. Hinshaw Jr. | President, Chief Executive Officer & Director |
| Alison D. Schecter | President of Strategy & Operations |
| Paul Fehlner | Senior Vice President, Chief Legal Officer & Corporate Secretary |
| Craig R. Jalbert | President, Chief Executive Officer, Treasurer, Secretary, Financial and Accounting Officer & Director |
| Marie Washburn | Vice President of Finance & Corporate Controller |
Poll Results
No votes yet today — be the first to share your view!
About Axcella Health Inc. (NASDAQ:AXLA) Stock
Axcella Health Inc. is a U.S.-based clinical-stage biotechnology firm focused on developing novel therapeutic compositions derived from endogenous metabolic modulators. These aim to address complex diseases and improve overall health. The company's primary drug candidates are AXA1665 and AXA1125. AXA1665 is currently undergoing Phase 2 clinical trials, where it is being evaluated for its potential to lower the risk of recurrent overt hepatic encephalopathy. Meanwhile, AXA1125 is progressing through multiple trials: a Phase 2b study targeting non-alcoholic steatohepatitis (NASH) treatment, and a Phase 2a study exploring its efficacy as a therapy for Long COVID patients. Founded in 2008, the entity initially operated as Newco LS16, Inc. before officially adopting the name Axcella Health Inc. ... in June 2016. Its operations are headquartered in Cambridge, Massachusetts.
Frequently Asked Questions
-
What is the current Axcella Health Inc. (AXLA) stock price?
-
Axcella Health Inc.(NASDAQ:AXLA) stock price is $4.58 in the last trading session. During the trading session, AXLA stock reached the peak price of $4.58 while $4.58 was the lowest point it dropped to. The percentage change in AXLA stock occurred in the recent session was 0.0% while the dollar amount for the price change in AXLA stock was $0.
-
AXLA's industry and sector of operation?
-
The NASDAQ listed AXLA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AXLA?
-
William R. Hinshaw Jr. | President, Chief Executive Officer & Director
Alison D. Schecter | President of Strategy & Operations
Paul Fehlner | Senior Vice President, Chief Legal Officer & Corporate Secretary
Craig R. Jalbert | President, Chief Executive Officer, Treasurer, Secretary, Financial and Accounting Officer & Director
Marie Washburn | Vice President of Finance & Corporate Controller -
How many employees does AXLA have?
-
Number of AXLA employees currently stands at 11. AXLA operates from 840 Memorial Drive, Cambridge, MA 02139, US.
-
Link for AXLA official website?
-
Official Website of AXLA is: https://www.axcellahealth.com
-
How do I contact AXLA?
-
AXLA could be contacted at phone #857 320 2200 and can also be accessed through its website. AXLA operates from 840 Memorial Drive, Cambridge, MA 02139, US.
-
How many shares of AXLA are traded daily?
-
The average number of AXLA shares traded daily for last 3 months was 37.08K.
-
What is the market cap of AXLA currently?
-
The market value of AXLA currently stands at $12.5M with its latest stock price at $4.58